Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Net Cash Flow (2022 - 2025)

Bioregenx (BRGX) has 4 years of Net Cash Flow data on record, last reported at -$6731.0 in Q3 2025.

  • For Q3 2025, Net Cash Flow fell 144.15% year-over-year to -$6731.0; the TTM value through Sep 2025 reached -$25076.0, down 278.35%, while the annual FY2024 figure was -$69974.0, 86.28% up from the prior year.
  • Net Cash Flow reached -$6731.0 in Q3 2025 per BRGX's latest filing, up from -$29972.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $68381.0 in Q4 2023 and bottomed at -$239056.0 in Q2 2023.
  • Average Net Cash Flow over 4 years is -$40877.5, with a median of -$12285.0 recorded in 2024.
  • The widest YoY moves for Net Cash Flow: up 8005.32% in 2023, down 28655.33% in 2023.
  • A 4-year view of Net Cash Flow shows it stood at -$865.0 in 2022, then skyrocketed by 8005.32% to $68381.0 in 2023, then plummeted by 122.89% to -$15653.0 in 2024, then soared by 57.0% to -$6731.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$6731.0 in Q3 2025, -$29972.0 in Q2 2025, and $27280.0 in Q1 2025.